The latest onvansertib data, and an abrupt CEO departure, spook investors.
ApexOnco Front Page
Recent articles
A phase 1 study of OKI-219 reads out imminently.
Majestec-9, in post-Darzalex multiple myeloma, is the latest success.
JNJ-95566692 enters phase 1, with Qilu neck and neck.
But the company still has a lot to prove with ERAS-0015.
Three private biotechs enter clinical trials, one targeting KRAS.
But PFS data are lacking, and there are questions about first and second-line plans.
The company will start three phase 3 trials of its G12D project this year.
